73 related articles for article (PubMed ID: 20670985)
21. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Runström A; Leanderson T; Ohlsson L; Axelsson B
J Neuroimmunol; 2006 Apr; 173(1-2):69-78. PubMed ID: 16472873
[TBL] [Abstract][Full Text] [Related]
23. Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE.
Campbell SJ; Meier U; Mardiguian S; Jiang Y; Littleton ET; Bristow A; Relton J; Connor TJ; Anthony DC
Brain Behav Immun; 2010 Jul; 24(5):738-46. PubMed ID: 20138139
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.
Chen X; Hu X; Zou Y; Pi R; Liu M; Wang T; Zheng X; Liu M; Lin M; Liu P; Tao L
J Neuroimmunol; 2009 May; 210(1-2):22-9. PubMed ID: 19344957
[TBL] [Abstract][Full Text] [Related]
25. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
[TBL] [Abstract][Full Text] [Related]
27. The influence of uric acid treatments on liver glutathione system prevent oxidative damages in experimental autoimmune encephalomyelitis mice.
Allameh A; Maleklou N; Zargari M; Sanati MH
Neurosci Lett; 2008 Jul; 439(1):111-5. PubMed ID: 18501514
[TBL] [Abstract][Full Text] [Related]
28. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
Palaszynski KM; Liu H; Loo KK; Voskuhl RR
J Neuroimmunol; 2004 Apr; 149(1-2):84-9. PubMed ID: 15020068
[TBL] [Abstract][Full Text] [Related]
29. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats.
Ruuls SR; de Labie MC; Weber KS; Botman CA; Groenestein RJ; Dijkstra CD; Olsson T; van der Meide PH
J Immunol; 1996 Dec; 157(12):5721-31. PubMed ID: 8955226
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic approach by Aloe vera in experimental model of multiple sclerosis.
Mirshafiey A; Aghily B; Namaki S; Razavi A; Ghazavi A; Ekhtiari P; Mosayebi G
Immunopharmacol Immunotoxicol; 2010 Sep; 32(3):410-5. PubMed ID: 20233107
[TBL] [Abstract][Full Text] [Related]
31. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of experimental autoimmune encephalomyelitis in C57 BL/6 mice by osthole, a natural coumarin.
Chen X; Pi R; Zou Y; Liu M; Ma X; Jiang Y; Mao X; Hu X
Eur J Pharmacol; 2010 Mar; 629(1-3):40-6. PubMed ID: 20006598
[TBL] [Abstract][Full Text] [Related]
33. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
34. Targeted expression of IGF-1 in the central nervous system fails to protect mice from experimental autoimmune encephalomyelitis.
Genoud S; Maricic I; Kumar V; Gage FH
J Neuroimmunol; 2005 Nov; 168(1-2):40-5. PubMed ID: 16120466
[TBL] [Abstract][Full Text] [Related]
35. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis.
Raikwar HP; Muthian G; Rajasingh J; Johnson C; Bright JJ
J Neuroimmunol; 2005 Oct; 167(1-2):99-107. PubMed ID: 16091293
[TBL] [Abstract][Full Text] [Related]
36. Oral Delivery of Methylthioadenosine to the Brain Employing Solid Lipid Nanoparticles: Pharmacokinetic, Behavioral, and Histopathological Evidences.
Kumar P; Sharma G; Gupta V; Kaur R; Thakur K; Malik R; Kumar A; Kaushal N; Katare OP; Raza K
AAPS PharmSciTech; 2019 Jan; 20(2):74. PubMed ID: 30631981
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of lymphocyte transformation by a naturally occurring metabolite: 5'-methylthioadenosine.
Vandenbark AA; Ferro AJ; Barney CL
Cell Immunol; 1980 Jan; 49(1):26-33. PubMed ID: 7351031
[No Abstract] [Full Text] [Related]
38. The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice.
Kuipers HF; Nagy N; Ruppert SM; Sunkari VG; Marshall PL; Gebe JA; Ishak HD; Keswani SG; Bollyky J; Frymoyer AR; Wight TN; Steinman L; Bollyky PL
Clin Exp Immunol; 2016 Sep; 185(3):372-81. PubMed ID: 27218304
[TBL] [Abstract][Full Text] [Related]
39. Inhbition of RNA synthesis in salivary glands of Drosophila melanogaster by 5'-methylthioadenosine.
Law RE; Sinibaldi RM; Cummings MR; Ferro AJ
Biochem Biophys Res Commun; 1976 Dec; 73(3):600-6. PubMed ID: 827291
[No Abstract] [Full Text] [Related]
40. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease.
Ahlem C; Auci D; Mangano K; Reading C; Frincke J; Stickney D; Nicoletti F
Ann N Y Acad Sci; 2009 Sep; 1173():781-90. PubMed ID: 19758229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
